SABCS 2018 Features Molecular Diagnostics Research

At the San Antonio Breast Cancer Symposium last week, researchers presented data from many studies exploring the use of molecular technologies to make patient care more precise.

They included studies exploring the ability of breast cancer recurrence molecular diagnostics to predict which patients are likely to experience a relapse and benefit from chemotherapy, as well as the cost-effectiveness of using these tools. Researchers also employed circulating tumor DNA technologies to try to identify which patients are likely to have a poor outcome and see their disease progress, and they conducted whole-genome sequencing studies to track the distinct genomic characteristics of metastatic breast cancer.

The market for breast cancer recurrence testing is a competitive one, where tests that can assess a patient’s risk for relapse, as well as their chance for benefitting from chemotherapy, have the advantage.

Source: https://www.genomeweb.com/cancer/sabcs-2018-features-molecular-diagnostics-research